Phase II clinical study of the safety and efficacy of sintilimab in combination with axitinib and stereotactic radiotherapy in the treatment of local-regional recurrent renal cell cancer.

被引：0
|
作者：
Liu, Ruiqi
Liu, Yang
Zhang, Zhiling
Gao, Jianming
Zhang, Xinyue
Pan, Qiwen
Li, Yilin
Cai, Lingling
Guo, Shengjie
Han, Hui
Zhou, Fangjian
Dong, Pei
He, Liru
机构：
[1] Sun Yat Sen Univ, Dept Radiat Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Dept Urol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16511
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
    Grabbert, Markus
    Grosu, Anca L.
    Zamboglou, Constantinos
    Gratzke, Christian
    EUROPEAN UROLOGY, 2022, 81 (06) : 622 - 622
  • [22] Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
    Masini, Cristina
    Iotti, Cinzia
    De Giorgi, Ugo
    Bellia, Roberto Salvatore
    Buti, Sebastiano
    Salaroli, Francesco
    Zampiva, Ilaria
    Mazzarotto, Renzo
    Mucciarini, Claudia
    Vitale, Maria Giuseppa
    Bruni, Alessio
    Lohr, Frank
    Procopio, Giuseppe
    Caffo, Orazio
    Nole, Franco
    Morelli, Franco
    Baier, Susanne
    Buttigliero, Consuelo
    Ciammella, Patrizia
    Timon, Giorgia
    Fantinel, Emanuela
    Carlinfante, Gabriele
    Berselli, Annalisa
    Pinto, Carmine
    EUROPEAN UROLOGY, 2022, 81 (03) : 274 - 282
  • [23] The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study
    Fujita, Masaki
    Matsumoto, Takemasa
    Inoue, Yuuichi
    Wataya, Hiroshi
    Takayama, Koichi
    Ishida, Masayuki
    Ebi, Noriyuki
    Kishimoto, Junji
    Ichinose, Yukito
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2016, 22 (04) : 235 - 239
  • [24] PHASE II CLINICAL STUDY OF TORIPALIMAB IN COMBINATION WITH STEREOTACTIC RADIOTHERAPY AS A NEOADJUVANT THERAPY FOR THE TREATMENT OF RESECTABLE (N1-N2) NON-SMALL CELL LUNG CANCER
    Wang, Zhen
    Zhu, Xi-Xu
    Song, Yong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A496 - A496
  • [25] Preliminary safety and efficacy results from phase II study pulsed radiotherapy with tislelizumab in patients with recurrent head & neck cancer
    Zhang, X.
    Chai, Y.
    Jiang, S.
    Liang, G.
    Wang, P.
    Yuan, Z.
    Tsunoki, T.
    Kadowaki, S.
    Mizuno, T.
    Ishizuka, Y.
    Sakakida, T.
    Narita, Y.
    Honda, K.
    Masuishi, T.
    Taniguchi, H.
    Ando, M.
    Muro, K.
    Hanai, N.
    ANNALS OF ONCOLOGY, 2024, 35
  • [26] A phase II clinical trial of capecitabine combined with recombinant human endostatin and stereotactic radiotherapy as firstaline treatment in patients with locally advanced pancreatic cancer.
    Shan, Jinglu
    Qing, Yi
    Li, Mengxia
    Sui, Jiangdong
    Zhang, Shiheng
    Feng, Yan
    Wang, Dong
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] A phase I/II, nonrandomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab, and capecitabine in patients with metastatic pancreatic cancer.
    Wilmink, J.
    Kordes, S.
    Klumpen, H.
    Richel, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Phase II study results on safety and efficacy of CAELYX® (DOXIL®) in combination with paclitaxel in the treatment of metastatic breast cancer
    Woll, PJ
    Carmichael, J
    Chan, S
    Howell, A
    Ranson, M
    Miles, D
    Calvert, H
    Welbank, H
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S322 - S322
  • [29] The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study
    Song, Meng-Jia
    Pan, Qiu-Zhong
    Ding, Ya
    Zeng, Jianxiong
    Dong, Pei
    Zhao, Jing-Jing
    Tang, Yan
    Li, Jingjing
    Zhang, Zhiling
    He, Junyi
    Yang, Jieying
    Huang, Yue
    Peng, Ruiqing
    Wang, Qi-Jing
    Gu, Jia-Mei
    He, Jia
    Li, Yong-Qiang
    Chen, Shi-Ping
    Huang, Rongxing
    Zhou, Zi-Qi
    Yang, Chaopin
    Han, Yulong
    Chen, Hao
    Liu, Heping
    Xia, Shangzhou
    Wan, Yang
    Weng, De-Sheng
    Xia, Liming
    Zhou, Fang-Jian
    Xia, Jian-Chuan
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021, 10 (03)
  • [30] Phase II trial of camrelizumab plus apatinib in combination with stereotactic body radiotherapy (SBRT) in patients with recurrent/metastatic non-clear-cell renal cell carcinoma (nccRCC)
    Liu, Ruiqi
    Liu, Yang
    Wei, Wensu
    Zhang, Zhiling
    Gao, Jianming
    Guo, Shengjie
    Han, Hui
    Zhou, Fangjian
    Dong, Pei
    He, Liru
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345